Author: Anna Smith

Cablivi gets positive results for rare blood clotting disorder

Sanofi’s Cablivi has been linked with a 74% reduction in aTTP-related death in a Phase III trial published by the New England Journal of Medicine.

HRT tablets associated with higher risk of blood clots

New research suggests that hormone replacement therapy (HRT) tablets are associated with a higher risk of rare but serious blood clots.

NICE says Novartis’ migraine drug Aimovig too costly for NHS

The National Institute for Health and Care Excellence (NICE) has rejected NHS funding for Novartis’ Aimovig (erenumab) as preventative treatment for migraine in draft guidelines.

New partnership to test oral paclitaxel

Athenex, Cancer Research UK’s Combinations Alliance and the NIHR Clinical Research Network Industry Alliance have formed a partnership that will test an experimental chemotherapy drug that can be taken orally.

Stivarga final NICE recommendation for hepatocellular carcinoma

Bayer’s Stivarga has received a final green light from the National Institute for Health and Care Excellence (NICE) for use by the NHS to treat advanced liver cancer.